Phase Ia/Ib study of RS-0139 a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer

PHASE IA/IB STUDY OF RS-0139 A NOVEL TUMOR-TARGETED DELIVERY OF DOCETAXEL, IN PATIENTS WITH RECURRENT, LOCALLY ADVANCED, OR METASTATIC NON-SMALL CELL LUNG CANCER ESMO 2022, 9-13 September, Paris 🡕 Abstract          ⤓ Poster Presenters Hakan Sedat Orer Citation Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064 Authors H.S. Orer1, G. Nomak2, B.O. Oksuzoglu3, R.S. Senturk4, Y. Eralp5, […]